Equities research analysts predict that Editas Medicine, Inc. (NASDAQ:EDIT) will report $1.87 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Editas Medicine’s earnings. The lowest sales estimate is $500,000.00 and the highest is $3.10 million. Editas Medicine reported sales of $960,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 94.8%. The company is expected to issue its next quarterly earnings report on Monday, November 6th.

According to Zacks, analysts expect that Editas Medicine will report full year sales of $1.87 million for the current fiscal year, with estimates ranging from $4.80 million to $23.28 million. For the next financial year, analysts expect that the firm will report sales of $23.31 million per share, with estimates ranging from $15.00 million to $39.03 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Editas Medicine.

Editas Medicine (NASDAQ:EDIT) last announced its earnings results on Wednesday, August 9th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). The business had revenue of $3.10 million during the quarter, compared to analyst estimates of $2.20 million. Editas Medicine had a negative net margin of 2,091.36% and a negative return on equity of 67.75%. The business’s revenue for the quarter was down 8.8% on a year-over-year basis. During the same period in the previous year, the company earned ($0.54) earnings per share.

A number of research firms have issued reports on EDIT. Morgan Stanley reaffirmed an “equal weight” rating and issued a $28.00 target price (up previously from $27.00) on shares of Editas Medicine in a report on Friday, October 6th. Zacks Investment Research downgraded Editas Medicine from a “hold” rating to a “sell” rating in a research report on Tuesday. ValuEngine upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. Cann reiterated a “hold” rating on shares of Editas Medicine in a research report on Thursday, August 10th. Finally, J P Morgan Chase & Co set a $27.00 price objective on Editas Medicine and gave the stock a “hold” rating in a research report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $25.88.

In other Editas Medicine news, insider Katrine Bosley sold 8,333 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $24.78, for a total value of $206,491.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 51,665 shares of company stock valued at $1,083,165 in the last quarter. Corporate insiders own 19.40% of the company’s stock.

Several hedge funds have recently made changes to their positions in EDIT. IHT Wealth Management LLC bought a new stake in shares of Editas Medicine in the 2nd quarter worth approximately $107,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Editas Medicine in the 2nd quarter worth approximately $127,000. Bank of America Corp DE lifted its position in shares of Editas Medicine by 72.2% in the 1st quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock worth $133,000 after acquiring an additional 2,489 shares during the period. Legal & General Group Plc lifted its position in shares of Editas Medicine by 308.4% in the 2nd quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock worth $145,000 after acquiring an additional 6,535 shares during the period. Finally, Creative Planning lifted its position in shares of Editas Medicine by 8,910.9% in the 2nd quarter. Creative Planning now owns 9,101 shares of the company’s stock worth $153,000 after acquiring an additional 9,000 shares during the period. Institutional investors own 69.37% of the company’s stock.

Shares of Editas Medicine (NASDAQ:EDIT) opened at 25.21 on Wednesday. The company’s 50 day moving average price is $22.61 and its 200 day moving average price is $22.61. The firm’s market capitalization is $1.03 billion. Editas Medicine has a 52-week low of $12.43 and a 52-week high of $28.50.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Expect Editas Medicine, Inc. (EDIT) Will Announce Quarterly Sales of $1.87 Million” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/11/zacks-brokerages-expect-editas-medicine-inc-edit-will-announce-quarterly-sales-of-1-87-million.html.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.